ONC
BeOne Medicines Ltd.NASDAQHealthcare$310.79+0.76%ClosedMarket Cap: $33.21B
As of 2026-04-06
Valuation
P/E (TTM)
115.74
PEG
0.80
P/B
11.48
P/S
6.78
EV/EBITDA
61.01
DCF Value
$-4,580.27
FCF Yield
2.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
86.9%
Operating Margin
8.4%
Net Margin
5.4%
ROE
7.3%
ROA
3.5%
ROIC
4.8%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $1.50B | 90.5% | $185.0M | $66.5M | $7.15 | — |
| FY 2025 | $5.34B | 87.5% | $447.1M | $286.9M | $32.89 | — |
| Q3 2025 | $1.41B | 86.1% | $163.1M | $124.8M | $13.52 | — |
| Q2 2025 | $1.32B | 87.5% | $87.9M | $94.3M | $0.84 | — |
| Q1 2025 | $1.12B | 85.2% | $11.1M | $1.3M | $0.01 | — |
| Q4 2024 | $1.13B | 85.8% | $-79.4M | $-151.9M | $-1.43 | — |
| FY 2024 | $3.81B | 84.4% | $-568.2M | $-644.8M | $-6.12 | — |
| Q3 2024 | $1.00B | 83.0% | $-120.3M | $-121.3M | $-1.16 | — |
| Q2 2024 | $929.2M | 85.1% | $-107.2M | $-120.4M | $-1.15 | — |
| Q1 2024 | $751.7M | 83.4% | $-261.3M | $-251.2M | $-2.47 | — |
| Q4 2023 | $634.4M | 83.3% | $-383.8M | $-367.6M | $-25.48 | — |
| FY 2023 | $2.46B | 84.5% | $-1.21B | $-881.7M | $-8.45 | — |